The Uncharted Territory of Preventing Alzheimer's The NHS is about to embark on a unique trial that will offer an experimental drug, Trontinemab, to individuals without symptoms who are at high risk of developing Alzheimer's disease.
This move marks a significant departure from the traditional approach of treating the condition after symptoms appear.
By recruiting 1,600 healthy adults aged 55 and 80 from across the globe, including the UK, the Surrey and Borders Partnership NHS Foundation Trust is pioneering an intervention that could potentially rewrite the script on how we prevent dementia.